Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ballou

Showing results (211-220 of 215) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 215 results.
Infection and Immunity|September 1, 1996
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malariaJ A Tine, D E Lanar, D M Smith, et al.
The Lancet. Infectious Diseases|March 23, 2020
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trialMilagritos D Tapia, Samba O Sow, Khardiata D Mbaye, et al.
Nature Reviews. Microbiology|June 25, 2024
The pathobiology of human fungal infectionsGordon D Brown, Elizabeth R Ballou, Steven Bates, et al.
The Journal of Infectious Diseases|June 2, 1998
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malariaC F Ockenhouse, P F Sun, D E Lanar, et al.
The Lancet. Infectious Diseases|March 23, 2020
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trialMilagritos D Tapia, Samba O Sow, Birahim P Ndiaye, et al.
Pageof 22

Showing results (211-220 of 215) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 215 results.
Infection and Immunity|September 1, 1996
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malariaJ A Tine, D E Lanar, D M Smith, et al.
The Lancet. Infectious Diseases|March 23, 2020
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trialMilagritos D Tapia, Samba O Sow, Khardiata D Mbaye, et al.
Nature Reviews. Microbiology|June 25, 2024
The pathobiology of human fungal infectionsGordon D Brown, Elizabeth R Ballou, Steven Bates, et al.
The Journal of Infectious Diseases|June 2, 1998
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malariaC F Ockenhouse, P F Sun, D E Lanar, et al.
The Lancet. Infectious Diseases|March 23, 2020
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trialMilagritos D Tapia, Samba O Sow, Birahim P Ndiaye, et al.
Pageof 22